Therapy Areas: Oncology
Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review
1 May 2026 - Australian pharmaceutical company Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced on Thursday that the marketing authorisation application (MAA) filed in Europe for TLX101...
FDB introduces gravimetric content to improve IV medication compounding
1 May 2026 - FDB (First Databank Inc), a provider of workflow-integrated drug knowledge for healthcare professionals, announced on Thursday the launch of its new gravimetric module, designed to help p...
Curocell secures full approval for RIMQARTO to enter CAR-T therapy market
30 April 2026 - Cell therapy company Curocell (KOSDAQ:372320) announced on Thursday that RIMQARTO Inj. (anbalcabtagene autoleucel) has received full regulatory approval from South Korea's Ministr...
European Commission clears first pertuzumab biosimilar in Europe
29 April 2026 - China-based biopharmaceutical company Shanghai Henlius Biotech Inc (HK:2696) and US healthcare company Organon (NYSE:OGN) announced on Wednesday that the European Commission has approv...
C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance
29 April 2026 - Chinese biopharmaceutical company C-Ray Therapeutics (Chengdu) Co Ltd announced on Tuesday that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has bee...
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
28 April 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for bepirovirsen for pr...